Consolidated and emerging inflammatory markers in coronary artery disease

Valter Lubrano, Silvana Balzan

Valter Lubrano, Fondazione G. Monasterio CNR-Regione Toscana, 56124 Pisa, Italy
Silvana Balzan, Institute of Clinical Physiology, CNR, 56124 Pisa, Italy

Author contributions: Lubrano V drafted the text; Balzan S contributed to the review and literature search.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Correspondence to: Dr. Valter Lubrano, Fondazione G. Monasterio CNR-Regione Toscana, Via Moruzzi n° 1, 56124 Pisa, Italy. walterl@ifc.cnr.it
Telephone: +39-050-3152199
Fax: +39-050-3153454
Received: August 13, 2014
Peer-review started: August 14, 2014
First decision: September 28, 2014
Revised: October 30, 2014
Accepted: November 19, 2014
Article in press: November 19, 2014
Published online: February 20, 2015

Abstract
Coronary artery disease is an event of atherosclerosis characterized by a chronic vascular inflammation. Risk factors like obesity, diabetes mellitus, hypertension, smoking, hypercholesterolemia and positive family history sometimes are not sufficiently adequate to the enhancement of cardiovascular risk assessment. In the past years numerous biomarkers, like C reactive protein, cytokines and adhesion molecules, have been observed to be related to adverse cardiovascular prognosis. Recently, several studies found an association among inflammatory biomarkers and cardiovascular diseases suggesting their utility to identify the risk of an acute ischemic event and the detection of vulnerable plaques. The emerging inflammatory markers are well divided for diagnosis and prognosis and plaque instability of coronary artery disease. Some of them, the lectin-like oxidized low density lipoprotein receptor-1 can be important both in diagnosis and in the evaluation of plaque instability, other are inserted in the above reported classification. The emerging inflammatory markers in acute-phase include amyloid A, fibrinogen and pentraxin 3 while myeloperoxidase, myeloid-related protein 8/14 and pregnancy-associated plasma protein-A are recognize markers of plaque instability. Lastly, some studies demonstrated that circulating miRNAs are involved in coronary artery disease, acute myocardial infarction and heart failure.

Key words: Coronary artery disease; Plaque instability; Inflammation; Acute phase; Biomarkers

© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: In this review we want to focus the reader’ s attention on the differences between inflammatory markers of cardiovascular risk already accepted by the scientific community and the emerging markers in order to encourage the healthcare services to improve laboratory techniques in early diagnosis and more precise evaluation of the risk. Is also important to use a classification according to the stage where the patient is located regarding emerging inflammatory markers for diagnosis, prognosis and plaque instability.

Lubrano V, Balzan S. Consolidated and emerging inflammatory markers in coronary artery disease. World J Exp Med 2015; 5(1): 21-32 Available from: URL: http://www.wjgnet.com/2220-315X/full/v5/i1/21.htm DOI: http://dx.doi.org/10.5493/wjem.v5.i1.21

INTRODUCTION
Atherosclerosis is largely recognized as a chronic inflam-
Inflammatory disorder caused by vascular and extravascular factors, and coronary artery disease (CAD) is its common manifestation. CAD could result in the development of acute coronary syndrome (ACS), which is often associated with breakage of an atherosclerotic plaque and partial or complete thrombosis of the related artery.

In recent years a large number of studies permitted a better knowledge of the events implicated in the progression of ACS: here we summarize them (Figure 1).

In these processes there is a recruitment of macrophages, that secretes lytic enzymes such as metalloproteinases. The atheroma core is constituted by foam cells and extracellular lipids shrouded by smooth-muscle cells and collagen matrix. Plaque ruptures release adhesion molecules and soluble factors, such as D-dimers, von Willebrand factor and plasminogen activator inhibitor-1 that have an important role in thrombus formation. In a few hours after thrombus formation, but before the initiation of coronary ischemia, albumin is released. Troponin, myoglobin, and creatine kinase-MB are time-dependent release components associated with myocardial necrosis (Figure 1). The extent of these events influences the circulating troponin level. Therefore it is important to identify the fundamental steps leading to atherosclerotic plaque rupture.

Adequate risk assessment remains the most challenging in individuals classified into low or intermediate risk categories. Inflammation is important in the progression of atherosclerosis and in plaque rupture. For this reason, numerous inflammatory markers have been extensively investigated as potential candidates for the enhancement of cardiovascular risk assessment.

Several recent studies have demonstrated the role of inflammation in mediating the stage of CAD, often caused by lipid accumulation.

Moreover the different part of atherogenesis could be related to inflammatory biomarkers that are important for clinical diagnosis, treatment and prognosis of patients with CAD. However, because conventional risk factors do not explain the changes in atherosclerosis, efforts have focused on developing novel biomarkers which identify vulnerable plaques and cardiovascular disease.

These new laboratory biomarkers should be standardized in variability, sensitivity and specificity from established risk markers. Finally, the cost of the assays has to be acceptable. In this review we analyze the inflammatory markers now considered valid in the stratification of risk for CAD and those emerging, checking if new ones can express something more than the standardized biomarkers.

CONSOLIDATED MARKERS

C-reactive protein

C-reactive protein (CRP), a pentraxin composed of 5 subunits, is an inflammatory marker that may increase in various pathological situations, synthesized mainly in the liver, but it is also produced by leukocytes and adipocytes.

According considerable evidence, during infection or tissue necrosis circulating CRP may increase 50000 times, but it is also regarded as an independent variable of future cardiovascular events.

CRP fosters antigen presentation and phagocytosis attaching to phosphocholine that is usually found in cell membranes and polysaccharides in prokaryotes and fungi and binding to complement C1q complex and factor H.

Moreover it can attach low density lipoprotein (LDL), and be identify within the plaque where it participates to inflammatory atherogenic processes. CRP is elevated
in patients with acute and chronic coronary syndromes in relation to the composition of the plaque and is related to the complications of heart failure. Low plasma levels of CRP indicate a good state of health, while increase when the style of life worsens. The MONICA Augsburg Study shows that low quality “Western” diet with low consumption of vegetables, fruit and fiber, extensive use of saturated fat, low physical activity and obesity, are associated with higher CRP levels.

Therefore, increment of CRP plasma concentration reflects not good lifestyle choices that lead to a metabolic disequilibrium and inflammation. The study of a large population has revealed that an increase in the levels of CRP (> 3 mg/L, elevated levels) was associated with mortality of 22962 subjects. Ridker et al. showed that CRP was a better biomarker of cardiovascular diseases than LDL cholesterol. However when measured together, they give better prognostic detail than measured separately. A large prospective study documented a strong association between CRP predictive power and the risks for coronary artery disease. Moreover, the Canadian Cardiovascular Society suggested that CRP evaluation in patients at “intermediate risk”, could represent a predictive risk of a cardiovascular event from 10% to nearly 20% within the subsequent 10 years. In agreement with this observation, the National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines and the American College of Cardiology Foundation-AHA Task Force on Practice Guidelines affirmed that the evaluation of CRP levels was acceptable for patients at intermediate risk.

Another study regarding people at intermediate risk for a cardiovascular event showed that the values of CRP and fibrinogen could help to prevent one additional event over a period of 10 years for every 400 to 500 people screened.

Current knowledge, however, suggests that the CRP concentration might reflect the vulnerability of the atheromatous lesion and the plaque rupture. The development of high-sensitivity CRP (hs-CRP) assays has been useful to investigate its role in predicting first cardiovascular events.

**Cytokines**

Interleukin 1 (IL-1), IL-6, IL-10, monocyte chemottractant protein-1 (MCP-1) and tumor necrosis factor alpha (TNF-α) are the main investigated cytokines among those which predict cardiovascular events involved in vascular inflammation and atherosclerosis. IL-1 and IL-6, regulate CRP production via direct stimulation of the hepatocytes. IL-6 may increase plaque instability modulating the expression of TNF-alpha, and MCP-1. Elevated IL-6 levels in healthy men correlated with increased risk for future MI independently from hs-CRP. According to some author IL-6 seems to be a marker more sensitive and specific than CRP in vascular inflammation and CRP studies show a weaker association with cardiovascular disease than cytokines. In the Fragmin study (FRISC-II), IL-6 increment above 5 ng/L was related with a mortality from 6- to 12-mo without a relationship with troponin and hs-CRP.

Therefore, IL-6 plasma concentration results as an effective independent index of increased mortality in unstable CAD and characterizes subjects who advantages of an initial invasive strategy. In addition, the intensity of plaque inflammation and its vulnerability seems to be linked with plasma IL-6 levels.

Some studies showed that IL-1 could have a regulatory function in the atherosclerotic development suggesting its modulation in vascular smooth muscle cell mitogenesis, in leukocyte adherence to vascular wall, in LDL metabolism, in extracellular matrix proteins and in vascular permeability. Moreover, IL-1 has been found to suppress vascular contractility and induce pro-coagulant activity.

Several years ago, increased levels of IL-1α and IL-1β were detected in human atherosclerotic plaque, suggesting their local synthesis. Moreover, IL-1 protein has been detected in macrophages from damaged carotid arteries. In the macrophages IL-1β secretion seems to be induced by the cholesterol crystals present into the plaque.

The presence of increased IL-1β plasma concentration in patients affected by unstable angina indicates its important role in the acute stage. However, in mouse models conflicting roles have been reported for IL-1β on the one hand the absence of IL-1β is associated with a reduction of atherosclerotic severity, on the other hand, IL-1β inactivation seems to be related to atherosclerotic plaque stability.

TNF-α plays a role in myocardial dysfunction and remodeling after acute coronary events. On behalf of this effect, the CARE study showed that TNF levels increased in recurrent coronary events after a MI compared with controls.

The chemokine MCP-1 recruits monocytes into the arterial wall activating these cells to induce endothelial injury. In addition, a positive correlation between MCP-1 levels and the extent of coronary atherosclerosis was found in the coronary circulation of patients with unstable angina. Moreover, MCP-1 levels have been found to correlate with older age, hypertension, hypercholesterolemia, and kidney failure, while an inverse correlation has been observed with estrogen replacement and HMG-CoA reductase inhibitor therapy. In several studies with small number of subjects, plasma MCP-1 levels were highest among patients with acute coronary syndromes (ACS), intermediate with stable coronary disease, and lowest among healthy control subjects.

IL-10 is an important factor for its anti-atherogenic property. In fact patients with high IL-10 levels had a reduced mortality compared with those that have only elevated CRP.

In 158 patients affected by stable CAD, during a 7-year follow-up period, the multivariate analysis of 10 cytokines showed IL-8 as the only independent marker for cardiovascular diseases. In summary, even if the results are still controversial, in our opinion among consolidated...
who underwent coronary stenting. Finally, another prospective study showed that only P-selectin and cardiac troponin I, but not the other CAMs, were significantly higher among patients who had a serious cardiac event during the subsequent 3 mo.

**EMERGING INFLAMMATORY MARKERS**

The lack of “traditional” risk factors cannot make totally free of the disease and new emerging markers of inflammation have been studied and classified according to their role in the development of coronary artery disease. TNF-α, Tumor necrosis factor alpha; IL: Interleukin; CRP: C-reactive protein; CAM: Adhesion molecules; OPG: Osteoprotegerin; OPN: Osteopontin. PAPP-A: Pregnancy-associated alpha plasma protein A; LOX-1: Lectin-like oxidized low-density lipoprotein receptor-1.

**Adhesion molecule**

Although very broad, adhesion molecules (CAMs) may be regarded as inflammatory markers of cardiovascular risk. Soluble CAMs (ICAM-1, VCAM, P and E selectines) are released from the surface of the cell and reflect cellular activation. CAMs induce the bind between leucocytes, platelets and vascular wall. After the adherence to the endothelium, the leucocytes transmigrate into the arterial wall determining the first phase of atherosclerosis. Several studies reported an association between the increase of plasma CAM concentration and the risk of cardiac events, but their role in CAD prognosis have not been established because their finding are still quite confused.

In patients with stable CAD, CAMs plasma concentrations were measured and informations on cardiovascular events were collected for some years. Among CAMs, only VCAM-1 resulted independently significant with future cardiovascular events.

In agreement with this study, other authors observed that the concentrations of sVCAM-1 > 780 ng/mL and CRP > 3 mg/L corresponded to a sensitivity > 90% for predicting future events in patients affected by acutely ACS.

On the contrary, other studies did not confirm these findings for sVCAM-1; instead, they suggested that CRP and sICAM-1 were useful for identifying the risk of a cardiac event in patients with unstable angina who underwent coronary stenting. Finally, another prospective study showed that only P-selectin and cardiac troponin I, but not the other CAMs, were significantly higher among patients who had a serious cardiac event during the subsequent 3 mo.

**EMERGING INFLAMMATORY MARKERS FOR DIAGNOSIS, PROGNOSIS AND PLAQUE INSTABILITY**

**Lectin-like oxidized low-density lipoprotein receptor-1**

Clinical studies have demonstrated that well-known coronary risk factors, including metabolic diseases, hypertension, obesity and smoking, are associated with oxidative stress. When the LDL are exposed to oxidative stress, they are caught in the vessel and oxidized (ox-LDL). Oxidized LDL promotes the synthesis of a large variety of cytokines and chemokines by the endothelium. Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1)
appears to be an important receptor for ox-LDL in endothelial cells\[73\]. LOX-1 not only allows the passage of oxidized lipids in the cells, but as already described, may cause endothelial dysfunction/apoptosis, inflammation, and the increase smooth muscle cell number favoring the formation of atheroma\[74-76\].

Moreover LOX-1 increment was observed to be associated with cardiovascular risk factors like hypertension and metabolic disorder. In a population of patients affected by CAD, our previous studies showed a positive relationship between circulating levels of LOX-1 and inflammatory markers: this work suggested also that LOX-1 levels increased with the severity of the disease\[76\] (Figure 3). Other authors underlined the importance of this novel biochemical marker for the stratification risk of the population and therapeutic strategy for CVD.

Overt cardiovascular disease is typically preceded by a long period of sub-clinical cardiovascular disease and sub-clinical atherosclerosis can be present for decades before the occurrence of a myocardial infarct event. Soluble LOX (sLOX-1) has shown to be informative either early or late in the process disease\[77-79\].

Recent study observed that the circulating levels of sLOX-1 are very high in acute coronary syndrome and that the plateau value is reached before troponin T, highlighting the instability of the plaque\[80\].

It has been reported that serum levels of sLOX-1 are also specifically elevated in acute coronary syndrome and the peak value has been reported to rise before troponin T\[80\]. In conclusion, sLOX-1 levels are related to the prognosis of acute coronary syndrome and reflect the instability of plaque\[80\].

Nuclear factor-kappa B, osteoprotegerin, osteocalcin, osteopontin, CD40

Receptor activator of nuclear factor Kappa-B ligand (RANKL) is the ligand of the receptor inducer factor-kB (NF-κB) and belongs to the family of cytokines TNF-related. It is synthesized by T cells and stromal/osteoblastic cells and is a strong chemotactic factor for human monocytes\[81\]. RANKL-stimulated microvascular endothelial cells favor monocyte adhesion and trans endothelial migration thus increasing the recruitment of osteoclast- and osteoblast like cell precursor\[82\].

Osteoprotegerin (OPG) synthesized in osteoblasts is part of the TNF super-family. It binds to RANKL thereby preventing interaction with its transmembrane receptor\[83\].

RANKL and OPG have been shown to be potentially valuable markers for a better assessment of coronary calcification and cardiovascular risk associated with it. It has been observed that RANKL and OPG may play a key role in maturation and calcification of atherosclerotic

\[\text{Figure 3 Regression analysis of LOX-1. From Lubrano et al}\[76\], 2008. Positive association between circulating levels of LOX-1 and inflammatory markers. TNF-α: Tumor necrosis factor alpha; IL: Interleukin; CRP: C-reactive protein; LOX-1: Lectin-like oxidized low-density lipoprotein receptor-1.\]
plaque\textsuperscript{[84-85]}. In fact these factors increased in serum of post-infarction of atherosclerotic animal models and of humans with unstable angina\textsuperscript{[90,97]}.

Osteocalcin, a protein found in bone and dentin and also synthetized in mononuclear cells, has been related with the severity of aortic calcification\textsuperscript{[89]}. Osteopontin (OPN), an extracellular matrix protein and pro-inflammatory cytokine, facilitates the recruitment of monocytes/macrophages through its adhesive domain\textsuperscript{[89]} and promotes the inhibition of vascular calcification. In fact it is increased in patients with vascular calcification resulting more like a marker than a mediator of atherosclerosis progression\textsuperscript{[90]}. CD40, a member of TNF family, is also a stimulatory receptor on antigen-presenting cells of the immune system that induces inflammatory processes through the binding of the CD40 ligand (CD40L). Elevated levels of soluble CD40L (sCD40L) have been found in patients with hypercholesterolemia, ACS and cardiovascular disease. sCD40L is also associated with atherosclerosis and plaque instability\textsuperscript{[90]}. In the CAPTURE trial, increased sCD40L (> 5 g/L) was related to a 6-mo mortality or nonfatal MI suggesting that sCD40L may be an independent risk marker of cardiovascular events. Statins, antihypertensive drugs, and antiplatelet agents have been shown to modulate it\textsuperscript{[90]}. Moreover, sCD40L was found to be increased in smokers and positively associated with both total cholesterol and biomarkers of inflammation. However, it was not reported as an independent biomarker for the risk of MI\textsuperscript{[90]}.

**ACUTE-PHASE RESPONSE PROTEIN**

Quantitative and qualitative changes of inflammatory markers are able to identify the acute stage of the disease. The plaque ruptures cause the consequent platelet aggregation and subsequent thrombosis, the final stage in which atherosclerosis leads to acute ischemic syndromes of AMI and sudden death\textsuperscript{[92]}. The literature well documented the association between serum concentrations of acute phase proteins and the onset of coronary heart disease and myocardial infarction\textsuperscript{[89,90]}. The emerging inflammatory markers in the acute-phase include pentraxin 3 (PTX3), amyloid A, and fibrinogen\textsuperscript{[96-102]}.

**Pentraxin-3**
Pentraxins are a superfamily of soluble proteins with cyclic multimeric structure\textsuperscript{[103]}. Among these, PTX3 a protein characterized by a long N-terminal domain, results as an important player in immunity and inflammation\textsuperscript{[104]}. Dendritic cells, macrophages and endothelial cells produce PTX3 in response to IL-1 and TNF\textsuperscript{[105]}. Moreover increased plasma PTX3 levels were observed in patients with cardiovascular disease and resulted also more closely related than CRP levels in acute phase of cardiac damages\textsuperscript{[90]} suggesting that it could be a sensitive and specific prognostic indicator\textsuperscript{[87]}. It has been also hypothesized an association of PTX3 in individuals with stable coronary artery disease and kidney dysfunction. However, an adjustment for the estimated glomerular filtration rate modestly attenuated these associations\textsuperscript{[106]}. By immune histochemical staining PTX3 was strongly expressed on the surface of lumen and within the atherosclerotic plaque in humans and animal models\textsuperscript{[86,97,99]}. Moreover, in the same experimental models, soluble PTX3 increased in the early phase after ischemic heart events and PTX3 mRNA and protein expression enhanced in the ischemic area of the heart\textsuperscript{[109]}.

In a prospective study of patients with myocardial infarction and ST elevation, PTX3 predicted 3-mo mortality while other markers such as the liver-derived short pentraxin CRP or NT-proBNP, Trnp, CK did not\textsuperscript{[107]}. In patients with unstable angina pectoris within the six hours of the chest pain, PTX3 resulted to be more specific for ACS than neutrophil activating peptide-2 and cardiac troponin I (cTnI)[111,113].

**Amyloid A**
Serum amyloid A (SAA) proteins are a family of apolipoproteins associated with high-density lipoprotein (HDL) and are now considered emerging markers of inflammation. In fact elevated SAA levels are present in coronary artery disease and indicate worse prognosis in CAD. Therefore actions involved to reduce SAA levels could improve the conditions of patients with acute CAD\textsuperscript{[113]}. A study of Kosuge et al\textsuperscript{[99]} reported that, in patients with ACS, increased SAA levels were associated with cardiovascular events within 30 d, without any relationship with CRP level. Therefore these data indicated SAA more useful predictor than CRP in these patients.

In the high serum SAA group the left ventricular ejection fraction, measured during follow-up, was significantly lower than in the low serum SAA group and more frequent complications, such as cardiac rupture, carcinogenic shock, subacute thrombosis, and cardiac death, were also present\textsuperscript{[108]}. Furthermore SAA levels were quite well associated with coronary artery disease with a predictive risk for cardiovascular events within 3 years, while this did not happen with hs-CRP\textsuperscript{[114]}. In a substudy of TIMI 11A, elevated SAA levels predicted increased risk of 14-d mortality in patients with ACS\textsuperscript{[113]}. In a Women Ischemia Syndrome Evaluation study, in which women were referred for coronary angiography because of suspected ischemia, elevated SAA values were correlated with angiographic severity of CAD and 3-year risk for cardiovascular events\textsuperscript{[114]}. At the same time, no relationship was observed between SAA levels and recurrent Coronary Events\textsuperscript{[116]}.

**Fibrinogen**
Several studies have indicated fibrinogen as a predictive marker in CAD\textsuperscript{[117]}. Fibrinogen is involved in platelet aggregation, endothelial injury, plasma viscosity and play a central role in the formation of thrombus. Epidemiological data have shown the important predictive role of fibrinogen in CAD, identifying it as an emerging risk factor because its measurement may improve the estimation of absolute risk obtained by conventional
risk factor for CV\(^{[117]}\).

Although it is still discussed the role of fibrinogen as inflammatory markers of risk, many studies indicated an association of hyperfibrinogenemia with atherothrombosis.

Already in the past, some authors have demonstrated that the risk estimation for CAD could be double when fibrinogenemia was also evaluated\(^{[118]}\).

Emerging Risk Factors Collaboration showed that, the measurement of fibrinogen level in patients at risk for CAD, could prevent an additional event in the next 10 years for every 400-500 people studied\(^{[119]}\).

However, also recent results show that the evaluation of fibrinogen during MI may be useful in identifying patients at high risks for future acute events\(^{[120]}\).

**BIOMARKERS OF PLAQUE INSTABILITY**

The main cause of the acute myocardial infarction (AMI) is the plaque rupture, so that it is important to investigate new markers for early diagnosis of plaque instability.

Due to its sensitivity and specificity, troponin is commonly used in the diagnosis of ACS, even if it provides only indirect details on myocardial necrosis induced by embolization of atherothrombotic material, late event of ACS.

Inflammation is a process that is intensified in plaque instability, so that the markers of inflammation may provide indications of cellular processes related to its formation before it occurs myocardial necrosis\(^{[121]}\).

**Myeloperoxidase**

Myeloperoxidase (MPO) is an enzyme produced by leukocytes that induces the formation of oxygen free radicals and is considered to be one major contributor in the formation and rupture of the plaque\(^{[21]}\).

In patients with ACS, MPO produced by neutrophils, is considered a marker of plaque vulnerability as noted by several studies\(^{[122, 123]}\).

Yunoki et al\(^{[124]}\) observed that the plasma levels of MPO have a significant inverse correlation with levels of paraoxonase-1 bound to HDL, especially in patients with stable and unstable angina pectoris, suggesting that a mismatch between pro oxidants and anti-oxidants may contribute to the progression of coronary plaque instability\(^{[124]}\).

**Myeloid-related protein 8/14**

Myeloid-related protein 8/14 (MRP8/14), is a heterodimer consisting of two proteins that bind calcium, calgranulin A and B, which play an important role in the signaling pathways of calcium, in cell cycle progression, cell differentiation, and in the interaction between the cytoskeleton and membrane\(^{[125]}\). MRP-8/14, also called calprotectin, is synthesized by activated monocytes and neutrophils, and is a pro-inflammatory protein expressed in atherosclerotic plaques.

High concentrations of MRP8/14 in the systemic circulation may reveal the presence of plaques before necrosis markers suggesting it as a good candidate for the management of ACS unstable.

**PAPP-A**

PAPP-A is a high-molecular-weight zinc-binding metalloproteinase. PAPP-A was independently associated with recurrent cardiovascular events in patients with ACS. This finding supported the potential usefulness of PAPP-A as a biomarker in patients with ACS\(^{[126]}\). Moreover as described by Mahto et al\(^{[127]}\) PAPP-A is the reliable marker which can discriminate the cases of MI from unstable angina and controls\(^{[127]}\). Another study has suggested PAPP-A to be a predictor of mortality or myocardial infarction in patients with ACS\(^{[128]}\).

**Role of microRNAs in CAD**

MicroRNAs (miRNAs) are short non-coding RNA molecules that regulate gene expression post-transcriptionally through suppression or degradation of target messenger RNA (mRNA).

MiRNAs were found in the circulating blood and are differently induced in patients with CAD, AMI, and heart failure\(^{[129-132]}\).

Of interest is miR-155, which proved to be a new component of inflammatory signal transduction pathways in the pathogenesis of atherosclerosis. In fact the expression of miR-155 is considered to be a prospective marker for predicting the prognosis of CAD since it is found to be expressed mainly in patients with CAD compared to healthy subjects\(^{[133]}\).

**CONCLUSION**

Inflammatory biomarkers appear to have an important prognostic value in patients with cardiovascular disease and may be useful in the diagnosis of apparently healthy subjects without known CAD who cannot be assessed with conventional risk factors.

Inflammatory biomarkers may have prognostic value for future cardiovascular risk among those at high risk or with documented cardiovascular disease. They also may be useful for identifying apparently healthy individuals, without known CAD, who may be at a higher risk than estimated by traditional risk factors.

Although recent data demonstrate that there is a close association between inflammatory biomarkers and coronary artery disease, further studies must be carried out taking into account also some important criteria typically used in the selection of a new biomarker: discrimination, calibration and reclassification, i.e. the ability of a test to discern between those that will face the disease from those that will be free, the assessment of the risk factor predicted and observed, classification in categories of low, intermediate and high risk for CAD\(^{[134]}\).

In our opinion the best candidate for this role is LOX-1; it was observed to be associated with cardiovascular risk factors like hypertension and metabolic disorder, showing its positive relationship with inflammatory markers and
its increment with the severity of the disease\textsuperscript{[90]} (Figure 3). Moreover it was elevated in acute coronary syndrome and the peak value has been reported to rise before troponin T reflecting the instability of plaque\textsuperscript{[80]}.

In conclusion, the findings observed in a decade showed that LOX-1 could represent an important marker for clinical characterization of coronary artery disease and a target for new drugs to reduce its expression and production.

ACKNOWLEDGMENTS

The authors are grateful to Lucrecia Mota Garcia for her English editing support and to Alison Frank for the final English revision.

REFERENCES

1. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 864-874 [PMID: 12490960]
2. Rader DJ. Inflammatory markers of coronary risk. N Engl J Med 2000; 343: 1179-1182 [PMID: 11036126]
3. Morrow DA, Braunwald E. Future of biomarkers in acute coronary syndromes: moving toward a multimarker strategy. Circulation 2003; 108: 250-252 [PMID: 12876133]
4. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (I). N Engl J Med 1992; 326: 242-250 [PMID: 17297776]
5. Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med 1999; 340: 115-126 [PMID: 9887164]
6. Piantini M. Role and importance of biochemical markers in clinical cardiology. Eur Heart J 2004; 25: 1187-1196 [PMID: 15246366]
7. Marian AJ, Nambi V. Biomarkers of cardiac disease. Expert Rev Mol Diagn 2004; 4: 805-820 [PMID: 15525223]
8. Lau DC, Dhillon B, Yan H, Szmitko PE, Verma S. Adipokines: molecular links between obesity and atherosclerosis. Am J Physiol Heart Circ Physiol 2005; 288: H2031-H2041 [PMID: 15655764]
9. Pepys MB, Hirschfeld GM. C-reactive protein: a critical update. J Clin Invest 2003; 111: 1805-1812 [PMID: 12813019]
10. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340: 448-454 [PMID: 9972870]
11. Okemeufuna AI, Nan R, Miller A, Gor J, Perkins SJ. Complement factor H binds to two independent sites to C-reactive protein in acute phase concentrations. J Biol Chem 2010; 285: 1053-1065 [PMID: 19850925 DOI: 10.1074/jbc.M109.04529]
12. Peisajovich A, Marnell L, Mold C, Du Clos TW. C-reactive protein at the interface between innate immunity and inflammation. Expert Rev Clin Immunol 2008; 4: 379-390 [PMID: 20476027 DOI: 10.1586/1744666X.4.3.379]
13. de Beer FC, Souar AK, Baltz ML, Traynor IM, Feinstein A, Pepys MB. Low density lipoprotein and very low density lipoprotein are selectively bound by aggregated C-reactive protein. J Exp Med 1982; 156: 230-242 [PMID: 7086355]
14. Jin C, Lu L, Zhang RY, Zhang Q, Ding FH, Chen QJ, Shen WF. Association of serum glycated albumin, C-reactive protein and ICAM-1 levels with diffuse coronary artery disease in patients with type 2 diabetes mellitus. Clin Chim Acta 2009; 408: 45-49 [PMID: 19615354]
15. Ridker PM. C-reactive protein: eighty years from discovery to clinical application of C-reactive protein across the spectrum of acute coronary syndromes. Clin Chem 2007; 53: 1800-1807 [PMID: 17717132]
16. Otake H, Shite J, Shinkle T, Watanabe S, Tanino Y, Ogawara D, Sawada T, Hirata K, Yokoyama M. Relation between plasma adiponectin, high-sensitivity C-reactive protein, and coronary plaque components in patients with acute coronary syndrome. Am J Cardiol 2008; 101: 1-7 [PMID: 18157966]
17. Scirica BM, Morrow DA, Cannon CP, de Lemos JA, Murphy S, Sabatine MS, Wiviott SD, Riffel N, McCabe CH, Braunwald E. Role and importance of circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2002; 347: 1557-1565 [PMID: 12432420]
18. Danesh J, Wheeler JC, Hirschfield GM, Esa S, Eiriksdottr G, Runold A, Lowe GD, Pepys MB, Gudnason V. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 1387-1397 [PMID: 15070788]
19. Ridker PM. C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2005; 353: 1021-1029 [PMID: 16096687]
20. Genest J, McPherson R, Frohlich M, Fischer HG, Löwel H, Döring A, Hutchinson WL, Pepys MB. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999; 99: 257-242 [PMID: 9802589]
21. Currie CJ, Poole CD, Conway PA. Evaluation of the association between the first observation and the longitudinal change in C-reactive protein, and all-cause mortality. Heart 2008; 94: 457-462 [PMID: 17761503]
22. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347: 1557-1565 [PMID: 12432420]
23. Danesh J, Wheeler JC, Hirschfield GM, Esa S, Eiriksdottr G, Runold A, Lowe GD, Pepys MB, Gudnason V. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 1387-1397 [PMID: 15070788]
24. Myers GL, Christenson RH, Cushman M, Ballantyne CM, Cooper GR, Pfeiffer FM, Grundy SM, Labarthe DR, Levy D, Rifai N, Wilson PW. National Academy of Clinical Biochemistry Laboratory Medicine Practice guidelines: emerging biomarkers for primary prevention of cardiovascular disease. Clin Chem 2005; 51: 378-384 [PMID: 15778197]
25. Greenland P, Alpert JS, Berlin JA, Beger MG, Budoff MJ, Fayad ZA, Foster E, Hlatky MA, Hodgson JM, Kloner RA, Levy D, Ritchie LD, Rifai N, Wilson PW. National Academy of Clinical Biochemistry Laboratory Medicine Practice guidelines: emerging biomarkers for primary prevention of cardiovascular disease. Clin Chem 2009; 55: 378-384 [PMID: 19016815]
26. Libby P. Molecular bases of the acute coronary syndromes. Circulation 1999; 91: 2844-2850 [PMID: 7758192]
27. Maseri A. Inflammation, atherosclerosis, and ischemic events – exploring the hidden side of the moon. N Engl J Med 1997;
Vascular permeability. Cell Biol 1985; 66: 26-31 [PMID: 3038513]
28 Boesken M, Boesken M, Reed NC, Hulea C, Neumann R, Will Removes. J Immunol 1985; 134: 1770-1780 [PMID: 3875708]
29 Hoefer MR, Hoefer MR, Sakurai H, Matsuda H, Sakurai H, Matsuda H, Sakurai H. Inhibition of leukocyte infiltration by interleukin-1. Am J Pathol 1988; 133: 895-904 [PMID: 3339426]
30 Nakamura K, Nakamura K, Yamashita T, Yamashita T, Yamashita T, Yamashita T, Yamashita T, Yamashita T. Expression of the IL-2 receptor on human vascular smooth muscle cells. J Mol Med 1985; 63: 313-320 [PMID: 3132497]
31 Murotani K, Murotani K, Kato M, Kato M, Kato M, Kato M, Kato M, Kato M. Induction of IL-1 and IL-6 in human aortic smooth muscle cells. J Clin Invest 1988; 81: 1767-1777 [PMID: 3076275]
32 Ficara V, Ficara V, Maggi S, Maggi S, Maggi S, Maggi S, Maggi S, Maggi S. Expression of IL-1 and IL-6 in human aortic smooth muscle cells: potential implications for inflammatory disease. Circulation 2000; 101: 1372-1378 [PMID: 10762679]
33 Gao L, Gao L, Liu Y, Liu Y, Liu Y, Liu Y, Liu Y, Liu Y. Expression of IL-1 and IL-6 in human aortic smooth muscle cells: potential implications for inflammatory disease. Circulation 2000; 101: 1372-1378 [PMID: 10762679]
34 Libby P, Libby P, Orodovs JM, Orodovs JM, Orodovs JM, Orodovs JM, Orodovs JM, Orodovs JM. Lipoprotein-induced expression of ICAM-1 and VCAM-1 in human aortic smooth muscle cells. J Biol Chem 1989; 264: 15591-15596 [PMID: 2986709]
35 Poblet D, Poblet D, Toldo J, Toldo J, Toldo J, Toldo J, Toldo J, Toldo J. Regulation of hepatic acute phase plasma protein genes by hepatitis C virus stimulating factors and other mediators of inflammation. Mol Cell Biol 1990; 10: 147-159 [PMID: 692952]
36 Schieffer B, Schieffer B, Hilfiker-Kleiner D, Hilfiker-Kleiner D, Hilfiker-Kleiner D, Hilfiker-Kleiner D, Hilfiker-Kleiner D, Hilfiker-Kleiner D. Expression of IL-1 and IL-6 in human aortic smooth muscle cells: potential implications for inflammatory disease. Circulation 2000; 101: 1372-1378 [PMID: 10762679]
37 Ridker PM, Ridker PM, Rifai N, Rifai N, Rifai N, Rifai N, Rifai N, Rifai N. Interleukin-1 enhances human vascular smooth muscle cell proliferation. J Immunol 1989; 142: 1427-1432 [PMID: 2497868]
38 Sviderskaya E, Sviderskaya E, Jaffe ES, Jaffe ES, Jaffe ES, Jaffe ES, Jaffe ES, Jaffe ES. Expression of IL-1 and IL-6 in human aortic smooth muscle cells: potential implications for inflammatory disease. Circulation 2000; 101: 1372-1378 [PMID: 10762679]
39 Asano M, Asano M, Moriwaki H, Moriwaki H, Moriwaki H, Moriwaki H, Moriwaki H, Moriwaki H. Interleukin-1 and IL-6 in human aortic smooth muscle cells: potential implications for inflammatory disease. Circulation 2000; 101: 1372-1378 [PMID: 10762679]
40 Iwakura Y, Iwakura Y, Asano M, Asano M, Moriwaki H, Moriwaki H, Moriwaki H, Moriwaki H. Lack of interleukin-1 receptor signals in human aortic smooth muscle cells. J Biol Chem 1989; 264: 15591-15596 [PMID: 2986709]
41 Carrafiello G, Carrafiello G, Tada H, Tada H, Tada H, Tada H, Tada H, Tada H. Expression of IL-1 and IL-6 in human aortic smooth muscle cells: potential implications for inflammatory disease. Circulation 2000; 101: 1372-1378 [PMID: 10762679]
42 Ridker PM, Ridker PM, Rifai N, Rifai N, Rifai N, Rifai N, Rifai N, Rifai N. Interleukin-1 enhances human vascular smooth muscle cell proliferation. J Immunol 1989; 142: 1427-1432 [PMID: 2497868]
43 Sviderskaya E, Sviderskaya E, Jaffe ES, Jaffe ES, Jaffe ES, Jaffe ES, Jaffe ES, Jaffe ES. Expression of IL-1 and IL-6 in human aortic smooth muscle cells: potential implications for inflammatory disease. Circulation 2000; 101: 1372-1378 [PMID: 10762679]
44 Iwakura Y, Iwakura Y, Asano M, Asano M, Moriwaki H, Moriwaki H, Moriwaki H, Moriwaki H. Lack of interleukin-1 receptor signals in human aortic smooth muscle cells. J Biol Chem 1989; 264: 15591-15596 [PMID: 2986709]
45 Carrafiello G, Carrafiello G, Tada H, Tada H, Tada H, Tada H, Tada H, Tada H. Expression of IL-1 and IL-6 in human aortic smooth muscle cells: potential implications for inflammatory disease. Circulation 2000; 101: 1372-1378 [PMID: 10762679]
46 Iwakura Y, Iwakura Y, Asano M, Asano M, Moriwaki H, Moriwaki H, Moriwaki H, Moriwaki H. Lack of interleukin-1 receptor signals in human aortic smooth muscle cells. J Biol Chem 1989; 264: 15591-15596 [PMID: 2986709]
47 Sviderskaya E, Sviderskaya E, Jaffe ES, Jaffe ES, Jaffe ES, Jaffe ES, Jaffe ES, Jaffe ES. Expression of IL-1 and IL-6 in human aortic smooth muscle cells: potential implications for inflammatory disease. Circulation 2000; 101: 1372-1378 [PMID: 10762679]
48 Iwakura Y, Iwakura Y, Asano M, Asano M, Moriwaki H, Moriwaki H, Moriwaki H, Moriwaki H. Lack of interleukin-1 receptor signals in human aortic smooth muscle cells. J Biol Chem 1989; 264: 15591-15596 [PMID: 2986709]
49 Carrafiello G, Carrafiello G, Tada H, Tada H, Tada H, Tada H, Tada H, Tada H. Expression of IL-1 and IL-6 in human aortic smooth muscle cells: potential implications for inflammatory disease. Circulation 2000; 101: 1372-1378 [PMID: 10762679]
50 Iwakura Y, Iwakura Y, Asano M, Asano M, Moriwaki H, Moriwaki H, Moriwaki H, Moriwaki H. Lack of interleukin-1 receptor signals in human aortic smooth muscle cells. J Biol Chem 1989; 264: 15591-15596 [PMID: 2986709]
51 Carrafiello G, Carrafiello G, Tada H, Tada H, Tada H, Tada H, Tada H, Tada H. Expression of IL-1 and IL-6 in human aortic smooth muscle cells: potential implications for inflammatory disease. Circulation 2000; 101: 1372-1378 [PMID: 10762679]
52 Iwakura Y, Iwakura Y, Asano M, Asano M, Moriwaki H, Moriwaki H, Moriwaki H, Moriwaki H. Lack of interleukin-1 receptor signals in human aortic smooth muscle cells. J Biol Chem 1989; 264: 15591-15596 [PMID: 2986709]
53 Carrafiello G, Carrafiello G, Tada H, Tada H, Tada H, Tada H, Tada H, Tada H. Expression of IL-1 and IL-6 in human aortic smooth muscle cells: potential implications for inflammatory disease. Circulation 2000; 101: 1372-1378 [PMID: 10762679]
54 Iwakura Y, Iwakura Y, Asano M, Asano M, Moriwaki H, Moriwaki H, Moriwaki H, Moriwaki H. Lack of interleukin-1 receptor signals in human aortic smooth muscle cells. J Biol Chem 1989; 264: 15591-15596 [PMID: 2986709]
55 Carrafiello G, Carrafiello G, Tada H, Tada H, Tada H, Tada H, Tada H, Tada H. Expression of IL-1 and IL-6 in human aortic smooth muscle cells: potential implications for inflammatory disease. Circulation 2000; 101: 1372-1378 [PMID: 10762679]
Lubrano V et al. Inflammatory markers in coronary artery disease

62 Störk S, Baumann K, von Schacky C, Angerer P. The effect of 17 beta-estradiol on MCP-1 serum levels in postmenopausal women. *Cardiovasc Res* 2002; 53: 642-649 [PMID: 11861035]

63 Heeschen C, Dimmeler S, Hamm CW, Fichtlscherer S, Boersma E, Thiele H. Elevation of the proinflammatory cytokine interleukin-10 is an important prognostic determinant in patients with acute coronary syndromes. *Circulation* 2003; 107: 2109-2114 [PMID: 12668510]

64 Inoue T, Komeda H, Nonaka M, Kameda M, Uchida T, Node K. Interleukin-18 as an independent predictor of long-term clinical outcome in patients with coronary artery disease. *Int J Cardiol* 2008; 124: 319-325 [PMID: 17442429]

65 Blankenberg S, Barbaux S, Tietz L. Adhesion molecules and atherosclerosis. *Atherosclerosis* 2003; 170: 191-203 [PMID: 14612198]

66 Nakashima Y, Raines EW, Plump AS, Breslow JL, Ross R. Upregulation of VCAM-1 and ICAM-1 at atherosclerotic-prone sites on the endothelium in the ApoE-deficient mouse. *Arterioscler Thromb Vasc Biol* 1998; 18: 842-851 [PMID: 9988485]

67 Ridker PM, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. *Circulation* 2001; 103: 491-495 [PMID: 11157711]

68 Mulvihill NT, Foley JB, Murphy R, Crean P, Walsh M. Evidence of prolonged inflammation in unstable angina and non-Q wave myocardial infarction. *J Am Coll Cardiol* 2000; 36: 1210-1216 [PMID: 11028472]

69 Blankenberg S, Rupprecht HJ, Bickel C, Peetz D, Hafner G, Tietz L, Meyer J. Circulating cell adhesion molecules and death in patients with coronary artery disease. *Circulation* 2001; 104: 1336-1342 [PMID: 11560847]

70 Mulvihill NT, Foley JB, Murphy RT, Curtin R, Crean PA, Walsh M. Risk stratification in unstable angina and non-Q wave myocardial infarction using soluble cell adhesion molecules. *Heart* 2001; 85: 623-627 [PMID: 11559739]

71 Doo YC, Han SJ, Park WJ, Kim SM, Choi SH, Cho GY, Hong KS, Han KR, Lee NH, Oh DJ, Ryu KH, Rhim CY, Lee KH, Lee Y. Associations between C-reactive protein and circulating cell adhesion molecules in patients with unstable angina undergoing coronary intervention and their clinical implication. *Clin Cardiol* 2005; 28: 47-51 [PMID: 15704532]

72 Hills GS, Terregino C,.Taggart P, Killian A, Zhao N, Dalsey MW, Mangione S. Elevated soluble P-selectin levels are associated with an increased risk of early adverse events in patients with presumed myocardial ischemia. *Am J Cardiol* 2002; 89: 1049-1052 [PMID: 12912804]

73 Murase T, Kume N, Kataoka H, Minami M, Sawamura T, Masaki T, Kita T. Identification of soluble forms of lectin-like oxidized LDL receptor-1. *Arterioscler Thromb Vasc Biol* 2000; 20: 715-720 [PMID: 10712396]

74 Inoue N, Sawamura T. Lectin-like oxidized LDL receptor-1 as extracellular chaperone receptor: its versatile functions and human diseases. *Methods* 2007; 43: 218-222 [PMID: 17920518]

75 Li D, Mehta JL. Antisense to LOX-1 inhibits oxidized LDL-mediated upregulation of monocyte chemotractant protein-1 and monocyte adhesion to human coronary artery endothelial cells. *Circulation* 2000; 101: 2889-2895 [PMID: 10869259]

76 Lubrano V, Del Turco S, Nicolini G, Di Cecco P, Basta G. Circulating levels of lectin-like oxidized low-density lipoprotein receptor-1 are associated with inflammatory markers. *Lipids* 2007; 42: 885-890 [PMID: 17853325]

77 Inoue N, Okamura T, Kubo Y, Fujita Y, Sato Y, Nakaniishi M, Yanagida K, Kakino A, Iwamoto S, Tanioka M, Ogura S, Otsui K, Matsuda H, Uchida K, Yoshimoto R, Sawamura T. LOX index, a novel predictive biochemical marker for coronary heart disease and stroke. *Clin Chem* 2010; 56: 550-558 [PMID: 20093560]

78 Kume N, Mitsuoka H, Hayashida K, Tanaka M, Kita T. Soluble lectin-like oxidized low-density lipoprotein receptor-1 predicts prognosis after acute coronary syndrome—a pilot study. *Circ J* 2010; 74: 1399-1404 [PMID: 20467054]

79 Kamezaki F, Yamashita K, Tasaki H, Kume N, Mitsuoka H, Kita T, Adachi T, Otsuji Y. Serum soluble lectin-like oxidized low-density lipoprotein receptor-1 correlates with oxidative stress markers in stable coronary artery disease. *Int J Cardiol* 2009; 134: 285-287 [PMID: 18367271 DOI: 10.1016/j.ijcard.2007.12.069]

80 Hayashida K, Kume N, Murase T, Minami M, Nakagawa D, Inada T, Tanaka M, Ueda A, Kominami G, Kambara H, Kimura T, Kita T. Serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels are elevated in acute coronary syndrome: a novel marker for early diagnosis. *Circulation* 2005; 112: 812-818 [PMID: 16061745]

81 Mosheimer BA, Kaneider NC, Feistritzer C, Sturm DH, Wiedermann CJ. Expression and function of RANK in human monocyte chemotaxis. *Arthritis Rheum* 2004; 50: 2309-2316 [PMID: 15248232]

82 Kindle L, Rothe L, Kriss M, Osadby P, Collin-Osdoby P. Human microvascular endothelial cell activation by IL-1 and TNF-alpha stimulates the adhesion and transendothelial migration of circulating human CD14+ monocytes that develop with RANKL into functional osteoclasts. *Bone Miner Res* 2006; 21: 193-206 [PMID: 16418775]

83 Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R, Nguyen HQ, Wooden S, Bennett L, Boone WC, Mangione A. Elevated soluble P-selectin levels are associated with the severity of aortic calcification. *Circulation* 2002; 105: 2461-2468 [PMID: 11583214]

84 Demer LL, Tintut Y. Vascular calcification: pathobiology of a multifaceted disease. *Circulation* 2008; 117: 2958-2948 [PMID: 18519861]

85 Ueland T, Yndestad A, Øie E, Florholmen G, Halvorsen B, Froland SS, Simonsen S, Christensen G, Gulstad L, Aukrust P. Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. *Circulation* 2005; 111: 2461-2468 [PMID: 15883214]

86 Sandberg WJ, Yndestad A, Øie E, Smith C, Ueland T, Ovchinnikova O, Robertson AK, Müller F, Semb AG, Schelz H, Andreassen AK, Gulstad L, Damás JK, Froland SS, Hansson GK, Halvorsen B, Aukrust P. Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization. *Arterioscler Thromb Vasc Biol* 2006; 26: 857-863 [PMID: 16424351]

87 Pal SN, Rush C, Parr A, Van Campenhout A, Gollek J. Osteocalcin positive mononuclear cells are associated with the severity of aortic calcification. *Atherosclerosis* 2010; 210: 88-95 [PMID: 20004897]

88 Smith LL, Cheung HK, Ling LE, Chen J, Sheppard D, Pytel R, Giachelli CM. Osteopontin N-terminal domain contains a cryptic adhesive sequence recognized by alpha5beta1 integrin. *J Biol Chem* 1996; 271: 28485-28491 [PMID: 8910476]

89 Scatena M, Liau L, Giachelli CM. Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. *Arterioscler Thromb Vasc Biol* 2007; 27: 2302-2309 [PMID: 17717292]

90 Schönböck U, Libby P. CD40 signaling and plaque instability. *Circ Res* 2001; 89: 1092-1103 [PMID: 11792273]

91 Varo N, de Lemos JA, Libby P, Morrow DA, Murphy SA, Nuzzo R, Gibson CM, Cannon CP, Braunwald E, Schönböck U. Soluble CD40L: risk prediction after acute coronary syndromes. *Circulation* 2003; 108: 1049-1052 [PMID: 12912804]

92 Jefferis BJ, Whincup PH, Welsh P, Wannamethee SG, Riumey A, Lawlor DA, Ebrahim S, Lowe GD. Prospective study
of circulating soluble CD40 ligand concentrations and the incidence of cardiovascular disease in a nested prospective case-control study of older men and women. J Thromb Haemost 2011; 9: 1452-1459 [PMID: 21696538 DOI: 10.1111/ j.1538-7836.2011.04145]

94 Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med 2003; 343: 1139-1147 [PMID: 11036199]

95 Biasucci LM, Liuzzo G, Grillo RL, Caligiuri G, Rebuzzi AG, Buffon A, Summaria F, Ginnetti F, Fadda G, Maseri A. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation 1999; 99: 855-860 [PMID: 10027905]

96 Rolph MS, Zimmem S, Bottazzi B, Garlanda C, Mantovani A, Hansson GK. Production of the long pentraxin PTX3 in advanced atherothrombotic plaques. Arterioscler Thromb Vasc Biol 2002; 22: e10-e14 [PMID: 12006411]

97 Peri G, Introna M, Corradi D, Iacucetti G, Signorini S, Avanzini F, Pizzetti F, Maggioni AP, Moccetti T, Metra M, Cas LD, Ghetti S, Pide JD, Re G, Olivetti G, Mantovani A, Latini R. PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation 2000; 102: 636-641 [PMID: 10931803]

98 Lee DH, Jeon HK, You JH, Park MY, Lee SJ, Kim SS, Shim Bjj, Choi YS, Shin WS, Lee JM, Park CS, Youn Hj, Chung WS, Kim JH. Pentraxin 3 as a novel marker predicting congestive heart failure in subjects with acute coronary syndrome. Koran Circ J 2010; 40: 570-576 [PMID: 20802050 DOI: 10.4070/ kj.2010.40.8.370]

99 Kosuge M, Ebina T, Ishikawa T, Hibi K, Tsukahara K, Okuda J, Iwahashi N, Ozaki H, Yano H, Kusama I, Nakati K, Katayama T, Umemura S, Kimura K. Serum amyloid A is a better marker of clinical outcomes than C-reactive protein in non-ST-segment elevation acute coronary syndromes. Circ J 2007; 71: 186-190 [PMID: 17251664]

100 Katayama T, Nakashima H, Takagi C, Honda Y, Suzuki S, Iwasaki Y, Yan K. Prognostic value of serum amyloid A protein in patients with acute myocardial infarction. Circ J 2005; 69: 1186-1191 [PMID: 16195614]

101 Reinhart WH. Fibrinogen—marker or mediator of vascular disease? Vasc Med 2003; 8: 211-216 [PMID: 14989564]

102 Coppola G, Rizzo M, Abrijani MG, Corrado E, Di Girolamo A, Brashi A, Braichi G, Novo S. Fibrinogen as a predictor of mortality after acute myocardial infarction: a forty-two-month follow-up study. Ital Heart J 2005; 6: 315-322 [PMID: 1590290]

103 Introna M, Alles VV, Castellano M, Picardi G, De Gioia L, Bottazzia B, Peri G, Breviario F, Salmona M, De Gregorio L, Dragani T, Srinivasan N, Blundell TL, Hamilton TA, Mantovani A. Cloning of mouse ptx3, a new member of the long pentraxin gene family expressed at extrahepatic sites. J Immunol 2000; 164: 2167-2216 [PMID: 11759264]

104 Lubrano V et al. Inflammatory markers in coronary artery disease.
Lubrano V et al. Inflammatory markers in coronary artery disease

Deeg D, Dekker JM, Engström G, Folsom AR, Fowkes FG, Gallacher J, Giampaoli S, Gillum RF, Hofman A, Howard BV, Ingelsson E, Iso H, Jürgensen T, Kiechl S, Kitamura A, Kiyohara Y, Koenig W, Kromhout D, Kuller LH, Lawlor DA, Meade TW, Nissen A, Nordestgaard BG, Onat A, Panagiotakos DB, Psaty BM, Rodríguez B, Rosengren A, Salomaa V, Kauhanen J, Salonen JT, Shaffer JA, Shea S, Ford I, Stehouwer CD, Strandberg TE, Tipping RW, Tosetto A, Wassefthell-Smoller S, Wennberg P, Westendorp RG, Whincup PH, Wilhelmsen L, Woodward M, Lowe GD, Wearham NJ, Khaw KT, Saltar N, Packard CJ, Gudnason V, Ridker PM, Pepys MB, Thompson SG, Danesh J. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med 2012; 367: 1310-1320 [PMID: 23040200 DOI: 10.1056/NEJMoa1107477]

120 Schäfer BW, Heizmann CW. The S100 family of EF-hand calcium-binding proteins: functions and pathology. Trends Biochem Sci 1996; 21: 134-140 [PMID: 8701470]

121 Nicholls SJ, Hazen SL. Myeloperoxidase and cardiovascular disease. Arterioscler Thromb Vasc Biol 2005; 25: 1102-1111 [PMID: 15790935]

122 Schaub N, Reichlin T, Meune C, Twerenbold R, Haaf P, Hochholzer W, Niederhauser N, Bosshard P, Stelzig C, Freese M, Reiter M, Gea J, Buser A, Mebazaa A, Osswald S, Mueller C. Markers of plaque instability in the early diagnosis and risk stratification of acute myocardial infarction. Clin Chem 2012; 58: 246-256 [PMID: 22057876 DOI: 10.1373/clinchem.2011.172940]

123 Baldus S, Heeschen C, Meintert T, Zeiher AM, Eiserich JP, Münzel T, Simoons ML, Hamm CW. Myeloperoxidase levels predict risk in patients with acute coronary syndromes. Circulation 2003; 108: 1440-1445 [PMID: 12952835]

124 Yunoki K, Naruko T, Inaba M, Inoue T, Nakagawa M, Sugioka K, Ohsawa M, Iwasa Y, Komatsu R, Itoh A, Haze K, Yoshiyama M, Becker AE, Ueda M. Gender-specific correlation between plasma myeloperoxidase levels and serum high-density lipoprotein-associated paraoxonase-1 levels in patients with stable and unstable coronary artery disease. Atherosclerosis 2013; 231: 308-314 [PMID: 24267244 DOI: 10.1016/j.atherosclerosis.2013.08.037]

125 Ionita MG, Vink A, Dijke IE, Laman JD, Peeters W, van der Woude DH, de Vries JP, Pasterkamp G, de Kleijn DP. High levels of myeloid-related protein 14 in human atherosclerotic plaques correlate with the characteristics of rupture-prone lesions. Arterioscler Thromb Vasc Biol 2009; 29: 1220-1227 [PMID: 19520974]

126 Bonaca MP, Scirica BM, Sabatine MS, Jarolim P, Murphy SA, Chamberlin JS, Rhodes DW, Southwick PC, Braunwald E, Morrow DA. Prospective evaluation of pregnancy-associated protein-A and outcomes in patients with acute coronary syndromes. J Am Coll Cardiol 2012; 60: 323-338 [PMID: 22813612 DOI: 10.1016/j.jacc.2012.02.023]

127 Mahto S, Sharma SB, Dwivedi S, Puri D, Tripathi RL. Biomarkers for early detection of risk in female patients with coronary artery disease: pilot study. J Assoc Physicians India 2013; 61: 317-319 [PMID: 24402944]

128 Iversen KK, Dalsgaard M, Teisner AS, Schoos M, Teisner B, Nielsen H, Grande P, Clemmensen P. Pregnancy-associated plasma protein-A, a marker for outcome in patients suspected for acute coronary syndrome. Clin Biochem 2010; 43: 851-857 [PMID: 20388505 DOI: 10.1016/j.clinbiochem.2010.03.018]

129 Fichtlscherer S, De Rosa S, Fox H, Schwietz T, Fischer A, Liebetrau C, Weber M, Hamm CW, Rößner T, Müller-Adelmann M, Bonauer A, Zeiher AM, Dimmeler S. Circulating microRNAs in patients with coronary artery disease. Circ Res 2010; 107: 677-684 [PMID: 20595655 DOI: 10.1161/circresaha.109.215566]

130 Wang GK, Zhu QJ, Zhang JT, Li Q, Li Y, He J, Qin YW, Jing Q. Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J 2010; 31: 659-666 [PMID: 20159880 DOI: 10.1093/eurheartj/ehq013]

131 Adachi T, Nakashima M, Otsuka Y, Nishimura K, Hirokawa G, Goto Y, Nonogi H, Iwai N. Plasma microRNA 499 as a biomarker of acute myocardial infarction. Clin Chem 2010; 56: 1183-1185 [PMID: 20395621]

132 Al J, Zhang R, Li Y, Pu J, Lu Y, Jiao J, Li K, Yu B, Li Z, Wang R, Wang L, Li Q, Wang N, Shan H, Li Z, Yang B. Circulating microRNA-1 as a novel potential biomarker for acute myocardial infarction. Biochem Biophys Res Commun 2010; 391: 73-77 [PMID: 19896465 DOI: 10.1016/j.bbrc.2009.11.005]

133 Zhu J, Chen T, Yang L, Li Z, Wong MM, Zheng X, Pan X, Zhang L, Yan H. Regulation of microRNA-155 in atherosclerotic inflammatory responses by targeting MAP3K10. PLoS One 2012; 7: e46551 [PMID: 23189122 DOI: 10.1371/journal.pone.0046551]

134 Wang TJ. Assessing the role of circulating, genetic, and imaging biomarkers in cardiovascular risk prediction. Circulation 2011; 123: 551-565 [PMID: 21309663 DOI: 10.1161/CIRCULATIONAHA.109.1915268]

P- Reviewer: Dong L, Lira FS S- Editor: Ji FF L- Editor: A E- Editor: Wu HL
